RSS Feeds
Search

Articles

Pharmalicensing brings you advice, commentary and analysis from industry experts.

Articles

No results found for given criteria.
Please try to put more general criteria into your selection.

Related Reports

Market Research Reports provided by reports.iptechex.com
FDA Withdraws Approval of Avastin in Breast Cancer
Jan 2011 - 4 pages - $500
Breast Cancer Drug Discoveries: what the future holds 2008: Chapter
Dec 2008 - 200 pages - $1,390
Drug Delivery Innovations Driving Improved Patient Compliance
Jul 2011 - 147 pages - $3,835
Rectal Cancer - Pipeline Review, Q3 2011
Jul 2011 - 206 pages - $500
Iniparib Failure: Highlights the Uncertainty in Late Stage Breast Cancer Pipeline
Mar 2011 - 5 pages - $500
Avastin and the AVADO Trial Survey
Feb 2008 - $2,500
Zoladex (Breast cancer) – Analysis and Forecasts to 2020
Oct 2011 - 47 pages - $2,000
Omnitarg (Breast Cancer) – Analysis and Forecasts to 2020
Oct 2011 - 52 pages - $2,000
Femara (Breast Cancer) – Analysis and Forecasts to 2020
Oct 2011 - 52 pages - $2,000
Aromasin (Breast Cancer) – Analysis and Forecasts to 2020
Oct 2011 - 48 pages - $2,000
More Related Market Research Reports >>>

Your selection

Industry sector
Drug delivery del
Rectal del
Sustained release del
Therapeutic target
Oncology del
Breast cancer del
Year
2002 del

Browse By

Therapeutic target
Adenocarcinoma
Breast cancer, other
Ductal carcinoma in situ
Invasive ductal breast cancer
Invasive lobular breast cancer
Lobular carcinoma in situ
Paget's Disease

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us